KIT amplification
|
Melanoma
|
KIT amplification
|
Melanoma
|
nilotinib Sensitive: C2 – Inclusion Criteria
|
nilotinib Sensitive: C2 – Inclusion Criteria
|
KIT amplification
|
Melanoma
|
KIT amplification
|
Melanoma
|
ripretinib Sensitive: C3 – Early Trials
|
ripretinib Sensitive: C3 – Early Trials
|